Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367739 | 0.81 | ADRB1 (0.42) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL3042980 | 0.80 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL23161511 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL3124652 | 0.80 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1TSHRPOLBLMNA | |
| SCHEMBL1239113 | 0.78 | KEAP1 (0.57) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL30851436 | 0.78 | KEAP1 (0.57) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL6005480 | 0.78 | KEAP1 (0.57) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL219341 | 0.77 | ADRB1 (0.59) | ALDH1A1KDM4ELMNAMAPTMEN1 | |
| SCHEMBL1267622 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL1447764 | 0.76 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337293-A | Therapeutic compound | 新泽西鲁特格斯州立大学 | 2019-10-15 | — | — | CN | claimed |
| EP-2678327-B9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-12-28 | — | — | EP | claimed |
| EP-2678327-B1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-08-17 | — | — | EP | claimed |
| US-9393247-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2016-07-19 | — | — | US | claimed |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | LUPIN LIMITED (IN) | 2015-08-20 | — | — | US | claimed |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-07-16 | — | — | US | claimed |
| US-9072731-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | claimed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | claimed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2013-12-12 | — | — | US | claimed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | claimed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005075477-A1 | ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | claimed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | claimed |
| US-4886805-A | Novel aminoalkylthio derivatives of triazolopyridine or triazoloquinoline, the processes for their preparation, and drugs, useful especially as analgesics, in which they are present | Centre D'Activite Et De Recherches Pharmaceutique Industrielle Biologique Medicale (FR) | 1989-12-12 | — | — | US | claimed |
| EP-0171005-B1 | XANTHINYLMETHYLTHIAZOLIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1989-11-23 | — | — | EP | claimed |
| EP-0254623-A1 | Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics | LABORATOIRES UPSA (FR) | 1988-01-27 | — | — | EP | claimed |
| EP-0171005-A2 | Xanthinylmethylthiazolidines, process for their preparation and pharmaceutical compositions containing them | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1986-02-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | SMN1; SMN2 4717/4885ALDH1A1 3383/4885KDM4E 3266/4885 |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | CHRNA7, CHRM1, CHRM2 | SMN1; SMN2 2518/4885ALDH1A1 3231/4885KDM4E 3110/4885 |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | TOP1, TOP2A, TOP2B | SMN1; SMN2 3873/4885ALDH1A1 811/4885KDM4E 2355/4885 |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | CHRNA7, CHRM1, CHRM2 | SMN1; SMN2 2301/4885ALDH1A1 2967/4885KDM4E 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.